Penemuan KESUM dalam LAKSA dan ASAM PEDAS, ada nilai hebat disebaliknya. KESUM mampu mendahului perubatan moden untuk melewatkan DEMENTIA & ALZHEIMER
REZEKI DAPAT BERJUMPA… TAHUKAN ANDA BELIAU PALING BANYAK MEMBANTU DEMI AGAMA.
SETELAH SELESAI PROGRAM DI AL-HIJRAH, LALU BERSETUJU DENGAN VIDEO (Tabung Derma).
Ustaz Mohammad Yaakub Yusra Mohd Yusof
Ustaz Mohammad Yaakub Yusra Mohd Yusof
Jutaan terima kasih.
Biokesum
The effects of six months Persicaria minor
extract supplement among older adults with mild cognitive impairment: a
double-blinded, randomized, and placebo-controlled trial
KESUM. #persicaria minor ✅
Abstract
Background: Persicaria minor extract exhibits antioxidant and anti-inflammatory
properties and has potential effects on cognitive function and mood. However,
the effects of P.minor on brain activation and biomarkers have not been studied
among older adults. This multicentre, randomized, double-blinded,
placebo-controlled study aimed to investigate the effect of 6 months P.minor
extract supplement (Biokesum®) on cognition, mood, biomarkers, and brain
activation among older adults with Mild Cognitive Impairment (MCI).
Method: A total of 36 Malaysian community-dwelling older adults with MCI
(60-75-year-old) were randomized into Biokesum® (n = 18) and placebo group (n =
18). Each subject consumed one capsule of Biokesum® (250 mg/capsule) or placebo
(maltodextrin, 280 mg/capsule) twice daily for 6 months. Cognitive function and
mood were assessed at baseline, 3rd, and 6th-month using neuropsychological
tests (MMSE, Digit Span, RAVLT, Digit Symbol, and Visual Reproduction) and
Profile of Mood State (POMS) questionnaire. Blood lipid profile, fasting blood
glucose, and biomarkers (MDA, LPO, COX-2, iNOS, and BDNF) were measured at
baseline and 6th month. By the end of the intervention, there were 30 compliers
(Biokesum®: N = 15; Placebo: N = 15) and 6 dropouts. For brain activation assessment,
15 subsamples (Biokesum®: N = 8; Placebo: N = 7) completed N-back and Stroop
tasks during fMRI scanning at baseline and 6th month. The dorsolateral
prefrontal cortex (Brodmann's area 9 and 46) was identified as a region of
interest (ROI) for brain activation analysis using SPM software.
Results: Two-way mixed ANOVA analysis showed significant improvements in Visual
Reproduction II (p = 0.012, partial η2 = 0.470), tension (p =
0.042, partial η2 = 0.147), anger (p = 0.010, partial η2 =
0.207), confusion (p = 0.041, partial η2 = 0.148), total
negative subscales (p = 0.043, partial η2 = 0.145), BDNF (p =
0.020, partial η2 = 0.179) and triglyceride (p = 0.029, partial
η2 = 0.237) following 6 months of Biokesum® supplementation.
Preliminary finding also demonstrated significant improvement at 0-back
task-induced right DLPFC activation (p = 0.028, partial η2 =
0.652) among subsamples in Biokesum® group. No adverse events were reported at
the end of the study.
Conclusion: Six months Biokesum® supplementation potentially improved visual memory,
negative mood, BDNF, and triglyceride levels among older adults with MCI.
Significant findings on brain activation at the right DPLFC must be considered
as preliminary.
Trial registration: Retrospectively registered on 30th August 2019 [
ISRC TN12417552 ].
Keywords: Brain-derived neurotrophic factor; Medicinal plants; Mild cognitive
impairment; Mood; fMRI.
Conflict of interest statement
No comments:
Post a Comment